West Virginia University Logo

122 protocol(s) meet the specified criteria

  • 1420-RDP-009A Phase 4 Multi-center, Ascending Dose, Open Label Study to Determine the Pharmacokinetics of Phenylephrine and the Pharmacodynamic Effects on Blood Pressure following Intravenous Administration of Phenylephrine Hydrochloride Injection, USP in Pediatric Subjects (>=12 to 16 years of age) Undergoing General and Neuroaxial Anesthesia
  • 16-009496Oncologic Outcomes Following Minimally Invasive Inguinal Lymphadenectomy for Melanoma
  • 20120123Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel Group Study to Characterize the Efficacy, Safety, and Tolerability of 24 Weeks of Evolocumab for Low Density Lipoprotein-cholesterol (LDL-C) Reduction, as Add-on to Diet and Lipid-lowering Therapy, in Pediatric Subjects 10 to 17 Years of Age With Heterozygous Familial Hypercholesterolemia (HeFH)
  • 2018-01Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors
  • 2125-MEL-301A Randomized Phase 3 Comparison of IMO-2125 with Ipilimumab versus Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma
  • 228446Vitamin D Supplementation in Children With Obesity-Related Asthma
  • A011104Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer
  • A011401Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
  • A011502A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
  • A021502Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
  • A031701A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (DDGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for those Patients whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations
  • A061202A PHASE I/II STUDY OF POMALIDOMIDE, DEXAMETHASONE AND IXAZOMIB VS. POMALIDOMIDE AND DEXAMETHASONE FOR PATIENTS WITH MULTIPLE MYELOMA RELAPSING ON LENALIDOMIDE AS PART OF FIRST LINE THERAPY
  • A081105Randomized Study of Erlotinib vs Observation in patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) ALCHEMIST
  • A151216Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
  • A5481082POLARIS: Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Multicenter Non-Interventional Study
  • ACE-LY-308A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP-196) in Subjects with Previously Untreated Mantle Cell Lymphoma
  • AFT-25Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS: A Phase III Prospective Randomized Trial
  • AL002Assessment of Safety and Efficacy of ExAblate Blood-Brain Barrier Disruption for the Treatment of Patients with Probable Alzheimer's Disease
  • APL-101-01Phase 1 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Advanced Solid Tumors and c-Met Dysregulation
  • BMMRDbMMRD - Biallelic Mismatch Repair Deficiency Syndrome Biobank
  • BMTCTN1506A Multi-center, Randomized, Double-blind, placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML
  • BP1001-201-AMLA Phase IIa, Open-label, Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of BP1001 (a Liposomal Grb2 Antisense Oligonucleotide) in Combination with Low-dose Cytarabine (LDAC) or Decitabine in Patients with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Induction Therapy
  • BPR-PIP-001An open-label study to evaluate the single-dose pharmacokinetics and safety of ceftobiprole in neonate and infant subjects aged up to 3 months undergoing treatment with systemic antibiotics
  • CA209648A Randomized Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin in Subjects With Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma
  • CCTL019B2003IManaged Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) in diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release
  • CFFC-OB-11A 10-Year Prospective Observational Study of the Incidence of and Risk Factors for Fibrosing Colonopathy in US Patients with Cystic Fibrosis Treated with CREON
  • CHEC-OB-17The CHEC-SC Cohort Study: CHaractErizing CFTR Modulated Changes in Sweat Chloride and their Association with Clinical Outcomes
  • COG-AALL1131A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum
  • COG-AALL1231AALL1231 - A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
  • COG-AALL1331Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND #117467, NSC #765986) i First Relapse of childhood B-Lymphoblastic Leukemia
  • COG-AALL15P1AALL15P1 - A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants with Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement
  • COG-AALL1621AALL1621 - A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND# 133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
  • COG-AALL1631International Phase 3 trial in Philadelphia chromosome-positive Acute Lymphoblastic Leukemia testing imatinib in combination with two different cytotoxic chemotherapy backbones.
  • COG-ACNS0831ACNS0831- Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years
  • COG-ACNS1422A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
  • COG-ACNS1721COG-ACNS1721 - A Phase 2 Study of Veliparib (ABT-888, IND # 139199) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600E Mutations
  • COG-AGCT1531A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
  • COG-AHEP1531COG-AHEP1531 - Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
  • COG-AHOD1331AHOD1331 - A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents
  • COG-ALTE1631ALTE1631 - A Randomized Web-based Physical Activity Intervention among Children and Adolescents with Acute Lymphoblastic Leukemia
  • COG-ANBL00B1Neuroblastoma Biology Studies
  • COG-ANBL1232COG-ANBL1232 - Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma - A Group Wide Historically Controlled Phase III Study
  • COG-ANBL1531Testing the Addition of 131I-MIBG or Crizotinib to Intensive Therapy in People With High-risk Neuroblastoma (NBL)
  • COG-ANBL1821A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# 141913) in Children with Relapsed, Refractory or Progressive Neuroblastoma
  • COG-APEC14B1APEC14B1 - Project: EveryChild - A Registry, Eligibility Screening, Biology and Outcome Study.
  • COG-APEC1621NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE)
  • COG-ARST1431A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
  • CONNECT-MDS-AMLCONNECT MDS/AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
  • DV3-MEL-01A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
  • E4512A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fushion Protein
  • EA1131A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
  • EA2165A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
  • EA4151A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission
  • EA5142Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
  • EA6134DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) Trial
  • EA9171Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
  • EAY131Molecular Analysis for Therapy Choice (MATCH)
  • EF-27Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
  • FASTFetal Atrial Flutter & Supraventricular Tachycardia Therapy Trial.
  • FAST-REGISTRYFast Registry Protocol: Prospective Observational Cohort Study of Fetal Atrial Flutter & Supraventricular Tachycardia
  • GO29432A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PDL1 Antibody) Compared with Gemcitabine + Cisplatin or Carboplatin for PD-L1-Selected, Chemotherapy Naive Patients with Stage IV Squamous Non-Small Cell Lung Cancer
  • GO39942A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab Vedotin in Combination with Rituximab and CHP (R-CHP) vs Rituximab and CHOP (R-CHOP) in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma
  • GOG-0238A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-Only or Recurrence of Carcinoma of the Uterine Corpus
  • GS-US-334-1113A Long Term Follow-up Registry for Adolescent and Pediatric Subjects Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials.
  • GTI-4419-301A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Superoxide Dismutase Mimetic GC4419 to Reduce Severe Oral Mucositis (SOM) Associated with Chemoradiotherapy for Locally Advanced, Non-Metastatic Head and Neck Cancer
  • INCB54828-302A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants with Unresectable or Metastatic Cholangiocarcinoma with FGFR2 Rearrangement
  • INCMGA-0012-201A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma
  • INTRAGO-IIA Multicenter Randomized Phase III Trial on Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme (INTRAGO II)
  • JZP963-201A Phase 2, Prospective, Randomized, Open-label Study on the Efficacy of Defibrotide Added to Standard of Care Immunoprophylaxis for the Prevention of Acute Graft-versus-Host-Disease in Adult and Pediatric Patients After Allogeneic Hematopoietic Stem Cell Transplant
  • M15-991A Multicenter, Randomized, Double-Blind,Placebo-Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment
  • N0577Phase III Intergroup Study of Temozolomide versus Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV chemotherapy in Patients with 1p/19q Codeleted Anaplastic Glioma
  • NRG-BR002A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
  • NRG-BR003A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
  • NRG-CC003Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer
  • NRG-GI004Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
  • NRG-GU002Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prosatectomy with or without Adjuvant Docetaxel.
  • NRG-GU005Phase III IGRT and SBRT versus IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
  • NRG-GU006A Phase II, Double-Blinded, Placebo Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-androgen Therapy With Apalutamide in Recurrent Prostate Cancer
  • NRG-GY006A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
  • NRG-HN004Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Stage III-IVB Head and Neck Cancer With a Contraindication to Cisplatin
  • NRG-LU002Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
  • NSABP-B51/RTOG-1304A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
  • NSABP-B59A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo
  • NSABP-FB12An Open-Label Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel Plus Trastuzumab and Pertuzumab in Early Stage HER2-Negative Breast Cancer Patients Selected with a Test Measuring Live Cell HER2 Signaling Transduction (FACT 1)
  • NSABP-FB14A Phase II Clinical Trial of Pembrolizumab in Combination with the AE37 Peptide Vaccine in Patients with Metastatic Triple-Negative Breast Cancer
  • NSMM-5001A global, prospective, non-interventional, observational study of presentation, treatment patterns, and outcomes in multiple myeloma patients - the INSIGHT-MM study
  • PB-102-F20A Randomized, Double blind, Active Control Study of the Safety and Efficacy of PRX-102 compared to Agalsidase Beta on Renal Function in Patients with Fabry Disease Previously Treated With Agalsidase Beta
  • PCI-32765CAN3001A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study
  • PCYC-1141-CAA Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma
  • PRE0404A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma
  • RLM-MD-01A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis
  • RRX001-211-01A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Lung Cancer, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Readministration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
  • S1616A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent
  • S1702A Phase II Study of Isatuximab for Patients with Previously Treated AL Amyloidosis
  • SAV005-04A Phase III, randomized, double-blind, placebo-controlled study of AeroVanc for the treatment of persistent methicillin-resistant Staphylococcus aureus lung infection in cystic fibrosis patients
  • SHP647-301A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as an Induction Therapy in Subjects with Moderate to Severe Ulcerative Colitis
  • SPR0028Performance of Epi proColon in Repeated Testing in the Intended Use Population (PERT)
  • STOP2-IP-15Standardized Treatment of Pulmonary Exacerbations II (STOP2)
  • STX-015-18-01A Prospective, Multicenter, Randomized, Double-Blinded, Sham-Controlled Study to Evaluate the Efficacy and Safety of Clonidine Micropellets for the Treatment of Pain Associated with Lumbosacral Radiculopathy in Adults: RePRIEVE-CM (achieving Radicular Pain RelIEf Via Epidural injection of Clonidine Micropellets)
  • TARGIT-BAn international randomised controlled trial to compare targeted intra-operative radiotherapy boost with conventional external beam radiotherapy boost after lumpectomy for breast cancer in women with a high risk of local recurrence.
  • TP-434-028A PHASE 1, OPEN-LABEL, MULTICENTER STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF INTRAVENOUS ERAVACYCLINE IN CHILDREN WITH SUSPECTED OR CONFIRMED BACTERIAL INFECTION
  • VX17-445-105A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation
  • WVU010318A Feasibility Study: Evaluating Carvedilol with Chemotherapy in Second Line Glioblastoma Multiforme and Response of Peripheral Glioma Circulating Tumor Cells
  • WVU010518Methionine-Restricted Diet to Potentiate Hypofractionated Radiation Therapy
  • WVU011113Tissue Procurement for Laboratory Studies Involving Novel Therapies for Breast Cancer
  • WVU011115Skeletal Muscle Tissue Procurement for the Study of Breast Cancer -Associated Gene Expression
  • WVU011117Serial ProspECtive bIopsy for Appalachian Lung Cancer Molecular Profiling (SPECIAL) Study
  • WVU011417Chemotherapy Induced Peripheral Neuropathy (CIPN) Development and Recovery in Women Treated for Breast Cancer: A Pilot Study
  • WVU011418Adherence to colorectal cancer screening in rural patients offered testing in a mobile mammography setting (Bonnie’s Bus Screening Study).
  • WVU01HSC19Accelerated rTMS as a treatment for post-stroke depression in the subacute phase: an open label pilot study
  • WVU01RNI18Pilot study to test wearable technology for COAT patients
  • WVU021118Skeletal Muscle Tissue Procurement for the Study of Metastatic Breast Cancer-Associated Gene and Protein Expression
  • WVU021119Evaluation of the Epigenetic Effects of Circulating DNA Methyltransferases and Histone Deacetylase Levels to Predict Toxicity from Radiation Therapy
  • WVU02HSC17Investigating human cognition with medically necessary intracranial electrophysiologic recordings
  • WVU03HSC18Maternal-neonatal dyad retrospective chart review of women with opioid use disorder in MAT
  • WVU03HSC19Rural Community Insights to Inform Opioid Epidemic Prevention Strategies
  • WVU04HSC16Alkaline Phosphatase and Sepsis in Patients Admitted Through the Emergency Department at Ruby Hospital
  • WVU04HSC19Rural Community Insights to Inform Opioid Epidemic Prevention Strategies Part 2. Mixed Methods
  • WVU05HSC17Role of Emotional Support in Head & Neck Cancer Patient Mood and Function
  • WVU06HSC17Repetitive Transcranial Magnetic Stimulation in Recently Abstinent Individuals with Opioid Use Disorder
  • WVU06HSC19Pathways Project Collaborative Phase II: Implementation of Kidney Supportive Care in Practice
  • WVU07HSC18Initial evaluation of clinical electron paramagnetic resonance (EPR) spectrometer using OxySPOT